Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial
Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical
activity, on the maintenance of weight reduction. Design, Setting, and Participants This
phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-
week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-
controlled period included adults with a body mass index greater than or equal to 30 or …
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical
activity, on the maintenance of weight reduction. Design, Setting, and Participants This
phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-
week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-
controlled period included adults with a body mass index greater than or equal to 30 or …
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)
Methods: SURMOUNT-4 is a phase 3, double-blind, 88-week study that investigates the
maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg QW), compared with placebo,
on the maintenance of weight loss for 52 weeks after an initial 36-week open-label
tirzepatide lead-in treatment period. In the study, participants without T2DM and with obesity
(BMI≥ 30 kg/m^ 2) or overweight (BMI≥ 27 kg/m^ 2) with at least 1 weight-related comorbid
condition were enrolled. The efficacy estimand was used to assess efficacy which …
maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg QW), compared with placebo,
on the maintenance of weight loss for 52 weeks after an initial 36-week open-label
tirzepatide lead-in treatment period. In the study, participants without T2DM and with obesity
(BMI≥ 30 kg/m^ 2) or overweight (BMI≥ 27 kg/m^ 2) with at least 1 weight-related comorbid
condition were enrolled. The efficacy estimand was used to assess efficacy which …